A Study With CIT-013 in RA Patients

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of RA patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of RA. Participants will: Take receive CIT-013 or placebo every other week for 6 weeks and 50 mg CIT-013 for 6 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

Key facts

Study ID: NCT06567470
Run by: Citryll BV
People needed: 88
Starts: 2025-07-29
Expected to finish: 2027-07-01
Last updated by the study team: 2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female patients with RA according to the 2010 classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) ≥ 3 months prior to screening
Aged 18-85
DAS28-CRP ≥ 3.2, with ≥ 3 Swollen Joints, and ≥ 3 Tender Joints, and CRP ≥ ULN at screening and confirmed prior to randomization
Stable on a conventional synthetic disease modifying antirheumatic drug for ≥ 4 weeks (csDMARD). This drug must have been used for ≥ 3 months.

You may not qualify if…

High clinical activity or disease severity requiring the immediate start of a biological DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD).
Contra-indication for CIT-013
Current inflammatory joint disease other than RA (Sjogren with active disease is included).
The washout period for bDMARD or JAKi prior to the first dose of investigational product should be at least:
≥ 1 week for etanercept;
≥ 4 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and sarilumab;
≥ 6 months year for rituximab;
≥ 2 weeks for tsDMARD (either investigational or commercially available treatment).
Treated with ≥ 3 bDMARD or tsDMARD
Injectable corticosteroids or treatment with > 10 mg/day dose of oral prednisolone or equivalent within 4 weeks prior to screening.

Where it is running

ES-03 — Santiago de Compostela, Spain (enrolling)
Site BE-01 — Leuven, Belgium (enrolling)
DE-04 — Bamberg, Germany (enrolling)
DE-05 — Berlin, Germany (enrolling)
DE-01 — München, Germany (enrolling)
DE-02 — München, Germany (enrolling)
ES-02 — A Coruña, Spain (enrolling)
ES-04 — Barcelona, Spain (enrolling)
ES-05 — Barcelona, Spain (enrolling)
ES-06 — Madrid, Spain (enrolling)
ES-01 — Santander, Spain (enrolling)
NL-05 — Leeuwarden, Netherlands (enrolling)
NL-01 — Rotterdam, Netherlands (enrolling)
PL-01 — Bialystok, Poland (enrolling)
PL-07 — Krakow, Poland (enrolling)
PL-03 — Lublin, Poland (enrolling)
PL-02 — Poznan, Poland (enrolling)
PL-05 — Torun, Poland (enrolling)
PL-04 — Warsaw, Poland (enrolling)
DE-03 — Ratingen, Germany
NL-02 — Amsterdam, Netherlands
BE-02 — Antwerp, Belgium
NL-04 — Leiden, Netherlands
NL-03 — Nijmegen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.